TAGRISSO (osimertinib)

TAGRISSO (osimertinib) is an EGFR TKI indicated for adult patients with locally advanced or metastatic EGFR T790M mutation-positive non-small cell lung cancer (NSCLC).1

Prescribing information

Dosing

TAGRISSO offers convenient, once-daily dosing1

Image showing TAGRISSO tablet dose
Image showing TAGRISSO tablet dose
 

Administration options:1

TAGRISSO is a once daily, 80 mg tablet
TAGRISSO is a once daily, 80 mg tablet

TAGRISSO is a once daily, 80 mg tablet1

TAGRISSO may be taken with or without food
TAGRISSO may be taken with or without food

TAGRISSO may be taken with or without food1

TAGRISSO can be dissolved in water and swallowed or taken through an NG tube
TAGRISSO can be dissolved in water and swallowed or taken through an NG tube

TAGRISSO can be dissolved in water and swallowed or taken through an NG tube1*

In patients treated with TAGRISSO 80 mg once daily, 2.3% had a dose reduction and 6.5% discontinued treatment due to adverse reactions or abnormal laboratory parameters.1

* TAGRISSO should not be crushed, split or chewed.1
TAGRISSO is not recommended in patients with severe hepatic impairment due to lack of current data.1

Some situations may require dose interruption or discontinuation:1

Image showing TAGRISSO tablet dose
Image showing TAGRISSO tablet dose